Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir Prophylaxis in HCV-Mismatched Kidney Transplant
NCT03627299Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of glecaprevir in hepatitis C (HCV), sponsored by Johns Hopkins University. Started Sep 2018; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03627299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627299.